M erkel cell carcinoma (MCC) is a potentially aggressive malignancy of the skin. With overall 2-year disease-specific mortality estimated at 28%, MCC has a poorer prognosis than melanoma. 1 Although rare, the incidence of MCC has tripled in the past 2 decades and continues to increase, generating greater attention for this malignancy. 2 Various clinical, histologic, and immunohistochemical features have been considered as prognostic indicators. In addition to clinical tumor diameter and presence of metastases, other factors are emerging that may be important in predicting prognosis. Results have been mixed; although recent studies report a positive association between tumor thickness, lymphovascular invasion, and infiltrative histologic growth pattern and poor outcome, [3] [4] [5] there is little uniformity in the clinical and histologic parameters reported with a diagnosis of a primary MCC, making it difficult to compare studies and examine potential prognostic variables. Furthermore, small sample sizes, attributable to this uncommon diagnosis, negatively affect the power of these studies and support the need for the collection of uniform data that may be shared across institutions.
Our purpose was to report a detailed descriptive analysis of prospectively collected clinical and histologic features in a contemporary cohort. Standardization of MCC data collected also provides an optimal framework for future outcome studies and the comparison and sharing of data.
Methods

Patients
The Institutional Review Board at the University of Michigan approved this study. Our prospective MCC database was queried for patients diagnosed with a primary MCC who underwent consultation in the Multidisciplinary MCC Program at the University of Michigan between February 2006 and March 2010. This identified 147 patients with a diagnosis of a new primary MCC. One patient developed a second primary MCC in the study period, and two had had a previous diagnosis of primary MCC in 2000 and 2001. Histopathology was reviewed for diagnostic confirmation by a dermatopathologist at the University of Michigan. A profile, including the histopathologic features below, was reported for each primary MCC. 6 
Variables
Clinical variables included patient sex, age, race, presence or absence of immunosuppression (medication-or disease-induced immunosuppression), history of other skin cancer (yes/no), history of other non-skin cancer (yes/no), site of the primary MCC (head or neck, trunk, arm, hand, leg or buttock, or foot), and clinical size (<1, 1-2, >2 cm). If the tumor was present at consultation, the faculty physician measured it. Otherwise, the size from the referring physician was recorded, or when not available, size was estimated using patient description, biopsy scar, or gross pathology description. Patients were staged at presentation according to the American Joint Committee on Cancer (AJCC) Seventh Edition (stage I, cutaneous disease only, 2 cm maximum tumor dimension; stage II, cutaneous disease only, >2 cm maximum tumor dimension; stage III, regional lymph node or in transit disease; stage IV, distant disease). 7 Clinical size was used for maximum tumor dimension. Fourteen (9.5%) patients were immunosuppressed: six with renal transplants, one with a lung transplant, four with chronic lymphocyte leukemia (CLL), and three taking immunosuppressive medication for other reasons (idiopathic pulmonary fibrosis, ulcerative colitis, rheumatoid arthritis). All immunosuppressed patients were Caucasian (8 male, 6 female). The mean age of presentation in these patients was 59.6, compared with 71.4 years in immunocompetent patients. Eightyone (55.1%) patients reported a history of other cancer types, skin and non-skin, at the time of presentation (Table 2) .
Main tumor characteristics, including histopathology features, are reported in Table 3 . Some characteristics had a smaller total number than the 150 total tumors because of nonstandardized histopathology in a minority of cases early in the study time period.
In 64 of 148 primary lesions (43.2%), clinical size was obtained by measuring the lesion at consultation at the University of Michigan, 28 (18.9%) were determined from the referring physician's description, 48 (32.4%) were estimated based on scar or patient description, 7 (4.7%) were obtained according to gross pathology description, and the source of clinical size measurement was unknown for one lesion. Lesions of <1 cm were more likely to be on the head and neck (64.9%, 37/57) than in other locations, but lesions 1 cm or more in clinical diameter were more common in other locations (67%, 61/91) than on the head and neck.
Discussion
Although the incidence of MCC is lower than with other cutaneous malignancies, the increasing incidence and potentially aggressive nature have directed attention toward this cancer. In this study, patient and tumor features were examined for the purpose of a detailed descriptive analysis from a contemporary, prospectively collected, singleinstitution database. 
Clinical Characteristics
Many clinical characteristics were similar to those reported in other studies. The majority of patients diagnosed with MCC are older Caucasians. [8] [9] [10] [11] [12] [13] [14] The mean age at diagnosis in our study was 70.3. Our data suggested a minimal male to female predominance of 1.1:1, compared with that reported by Heath and colleagues of 1.4:1. 10 In our study, 45.3% of lesions occurred on the head and neck and 50.0% on the extremities, including the buttocks.
Others have reported frequencies of 29 to 62.5% on the head and neck and 33 to 52% on the extremities, including the buttocks. 10, 11, 13 In our study, 9.5% of patients were immunosuppressed. Numerous studies support an association between MCC and immunosuppression. MedinaFranco and colleagues, in a review of seven studies, reported that 14.5% of patients had received or were receiving immunosuppressive therapy, and Heath and colleagues reported that 7.8% of their cohort were profoundly immunosuppressed (human immunodeficiency virus, chronic lymphocytic leukemia (CLL), solid organ transplant). 10, 13 Observations of MCC in transplant patients and patients with autoimmune disease taking immunosuppressant drugs indicate that long-term iatrogenic immunosuppression increases the risk of MCC. 15 In the study by Heath and colleagues, age at diagnosis was comparable in immunosuppressed and immunocompetent patients, 10 but in our study, immunosuppressed patients were on average more than 10 years younger than immunocompetent patients at diagnosis. In organ transplant patients, the mean age at diagnosis has been reported as 53. 16 Other malignancies have been identified with a high incidence in individuals with MCC. According to Howard and colleagues, in patients with other first primary cancers, the risk of developing MCC as a second primary malignancy was 1.36 times as great. 17 In our study, 55.1% of patients had a diagnosis of a non-MCC cancer before diagnosis of MCC. History of a non-MCC skin cancer, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, occurred in 43.5% of patients. BCC occurred most commonly, followed by SCC and then melanoma. Others have also found a high incidence of skin cancers in patients with MCC. 13, 18, 19 In our cohort, 21.1% of patients had a history of SCC, somewhat lower than the 34 to 41% in other reports that, unlike our study, included SCC after presentation of MCC. [19] [20] [21] Twenty-eight (19.0%) patients had a diagnosis of a non-skin cancer before diagnosis of MCC. Ten patients were diagnosed with a hematologic malignancy, 
Tumor Characteristics
Tumor size is a dominant factor in staging, but until recently, use of multiple staging systems has led to confusion and inconsistencies among health care providers, patients, and researchers. 23 In late 2009, the AJCC adopted a consensus staging system in which the maximum dimension of the tumor plays an important role in staging, 7 but the method of measuring is not defined and may be interpreted as clinical (clinical size) or histologic (greatest histologic horizontal dimension). In this study, three distinct size measurements were recorded for each primary MCC-clinical size, greatest histologic horizontal dimension, and tumor thicknessalthough it remains to be determined whether one of these measurements is superior to the others at predicting outcome. Historically, clinically measured sizes have been the standard, yet as in our study, we would expect considerable variability in how clinical size is obtained. Ideally, study physicians would measure clinical size, but in referral medical centers, a partial or complete biopsy has often prompted patients' referral. In these instances, when available, we used measurements that referring physicians obtained. In other instances, we had only patient description or biopsy scar length available, which is a suboptimal means of measurement.
In the literature, how clinical size measurement is obtained is frequently lacking but would be expected to be variable as well. This may have implications for the prognostic strength of clinical size in comparison with the other measurements of tumor size. Greatest histologic horizontal dimension would be expected to underestimate clinical size in part because of shrinkage that occurs with standard formalin-fixed permanent section tissue processing. 24 In this study, the mean greatest histologic horizontal dimension was 9.07 mm for tumors with clinical size of 1 to 2 cm and 16.38 mm for tumors with clinical size >2 cm. In this study, if greatest histologic horizontal dimension rather than clinical size was used for staging, 18 primary MCCs would have been understaged. Tumor thickness has the potential to be a strong prognostic indicator. Recent studies report a positive association between greater tumor thickness and poor outcome. 3 Other studies have found no correlation between tumor thickness and disease-free or overall survival. 25 Using measurements from biopsy and re-excision if residual tumor is present, tumor thickness may be the most reproducible and reviewable. A consistent and systematic way to measure and report lesion size is critical for staging and downstream clinical decision-making and management.
In our series, tumors were smaller than those reported in the literature, with 38.0% of primary lesions smaller than 1 cm, 32.0% 1 to 2 cm, and 28.7% larger than 2 cm in clinical diameter. In the study by Heath and colleagues of patients diagnosed with MCC between 1980 and 2007, 21.3% of primary lesions were smaller than 1 cm, 43.3% were 1 to 2 cm, and 35.3% were larger than 2 cm in clinical diameter. 10 Similarly, in our study, mean greatest histologic horizontal diameter was 9.5 mm, compared with a mean of 20.1 mm reported in a S C H W A R T Z E T A L study of 156 patients over 25 years. 3 It is likely that, with increased awareness of MCC and skin cancer in general, diagnosis occurs earlier in the disease course.
Various other histologic factors included in our primary MCC profile have been considered in analyses of prognostic variables in the literature, mostly small studies, including anatomic level of invasion, mitotic rate, growth pattern, ulceration, and angiolymphatic invasion. [3] [4] [5] [26] [27] [28] [29] [30] In 96.9% of our patients, the primary MCC extended to anatomic level IV or V, and in 54.5%, the tumor involved the subcutis (level V). In a study by Andea and colleagues, the deepest anatomic compartment involved by tumor was significantly associated with survival. 3 Some smaller studies support this, but others do not. 27, 29, 30 Few studies report on mitotic rate in primary MCC. In this study, the mean mitotic rate was 29/ mm 2 (range 1-96/mm 2 ). Skelton and colleagues found that higher mitotic rates were associated with lower survival rates, but two smaller studies failed to show a correlation. [28] [29] [30] Our prior study found that greater mitotic rate was significantly associated with greater likelihood of a positive sentinel lymph node in MCC. 31 In our cohort, 53.4% of tumors had a circumscribed growth pattern, and 46.6% had an infiltrative pattern. Histologic growth pattern has been shown to have prognostic significance in some studies. 3, 29 Andea and colleagues reported that a circumscribed pattern was associated with longer survival, whereas an infiltrative pattern had a poorer prognosis. 3 We previously reported that an infiltrative pattern was significantly associated with a greater likelihood of a positive sentinel lymph node. 31 Several small studies have not shown significance of histologic growth pattern as a prognostic marker in MCC. 28, 30 Ulceration was present in only 10.6% of primary MCCs in this cohort. Similarly, Andea and colleagues reported ulceration in 8% of their patients. 3 Ulceration has not been shown to correlate significantly with prognosis. 3, [28] [29] [30] Angiolymphatic invasion has been reported to occur in 30 to 60% of MCCs and, in our study, occurred in 33.1%. [3] [4] [5] [28] [29] [30] In the study by Fields and colleagues, lymphovascular invasion was present in 56% of the primary tumors in which the status was reported. 4 The discrepancy in the percentage of tumors with lymphovascular invasion between the study by Fields and colleagues and our study may be attributable to the use of immunohistochemistry in the former study to evaluate for angiolymphatic invasion in tumors initially found to be negative on hematoxylin and eosin evaluation. Andea and colleagues found lymphovascular invasion to be an independent predictor of survival on multivariate analysis, and in the study by Fields and colleagues, the presence of lymphovascular invasion was significantly associated with greater disease-specific death. 3, 4 Other studies have failed to show a significant correlation between angiolymphatic invasion and survival. [28] [29] [30] 
Conclusion
This study presents a cross-sectional analysis of a modern prospectively maintained database with consistent pathology review. Histopathologic profiling of primary MCC in the literature is variable and limited, yet the importance of an accurate histopathologic profile for primary MCC cannot be overstated. 6, 32 Prospective documentation of these histologic parameters and clinical features, presented in Table 4 , is needed to meaningfully analyze these for prognostic significance and to identify the important independent clinical and histologic features that best predict outcome. In the future, because of the rarity of the tumor, systematic prospective collection of detailed MCC data can be used to provide the framework for rigorous outcome studies and the ability to compare and share data from multiple sources.
